Technohal

prof.dr. S. Siesling (Sabine)

Full Professor
BMS-TPS-HTSR
Technohal 3105
s.siesling@utwente.nl
+31534895638
Business card

Sabine Siesling, clinical epidemiologist, is professor ā€˜Outcomes Research and Personalized cancer careā€™ at the University of Twente andā€Æsenior researcher at the Netherlands Comprehensive Cancer Organisation (IKNL). She focusses on the effect of interventions, such as care pathways or implementation of new technologies, on the quality, organisation and outcome of cancer care. She tailors care and follow-up using/developing prediction models which are based on data from e.g. the Netherlands Cancer registry. She is board member of the National breast cancer working group (NABON) and the NABON Breast cancer audit and PROMS sections, and the European Initiative on Breast cancer Care-Quality assurance Development group. Moreover, she leads the program on Womenā€™s Health at the University of Twente.Ā Ā 


She has been president of the Netherlands Epidemiological Society.Ā Ā 

Expertise

  • Medicine and Dentistry

    • Breast Cancer
    • Patient
    • Therapeutic Procedure
    • Cancer Registry
    • Survival
    • Neoplasm
    • Hospital
    • Malignant Neoplasm

Organisations

Ancillary activities

  • Integraal Kankercentrum Nederland (IKNL)headresearcher

Publications

Jump to: 2025 | 2024

2025

Different needs ask for different care: Breast cancer patientsā€™ preferences regarding assessment of care needs and information provision in personalized aftercare (2025)European journal of oncology nursing, 76. Article 102873. Dekker-Klaassen, A., Drossaert, C. H. C., Folkert, L. S., van der Lee, M. L., Guerrero-Paez, C., Claassen, S., Korevaar, J. C., Siesling, S., Maaren, M. v., Retel, V., Leeuwen, E. v., Knottnerus, B., Burgers, J., Vrancken, M. J., Siemerink, E., Honkoop, A., Veltman, J., Zeillemaker, A., Mann, R., ā€¦ Hezewijk, M. v.https://doi.org/10.1016/j.ejon.2025.102873Notification of locoregional breast cancer recurrence based on pathology reports: A nationwide validation study with the Netherlands Cancer Registry (2025)Cancer epidemiology, 96. Article 102780. van Maaren, M. C., Voorham, Q. J. M., Wijnen, E. M., de Munck, L., Wesseling, J., Visser, O. & Siesling, S.https://doi.org/10.1016/j.canep.2025.102780Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients (2025)European journal of cancer, 222. Article 115475. Ding, N., Hermans, K. E. P. E., van Nijnatten, T. J. A., Engelen, S. M. E., Tol, J., Kooreman, L., Vrancken-Peeters, M.-J. T. F. D., Siesling, S., Voogd, A. C., Tjan-Heijnen, V. C. G. & Geurts, S. M. E.https://doi.org/10.1016/j.ejca.2025.115475Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A realā€world evidence study (2025)International journal of cancer, 156(10), 1950-1960. Slotman, E., Pape, M., van Laarhoven, H. W. M., Pouw, R. E., van der Linden, Y. M., Verhoeven, R. H. A., Siesling, S., Fransen, H. P. & Raijmakers, N. J. H.https://doi.org/10.1002/ijc.35314ASO Author Reflections: Sentinel Lymph Node Biopsy for Patients with a Non-classic Lobular Carcinoma In Situ Breast Biopsy (2025)Annals of surgical oncology, 32, 2597-2598. Article 113500. Westenend, P. J., Meurs, C. J. C., Siesling, S. & Menke-Pluijmers, M. B. E.https://doi.org/10.1245/s10434-024-16863-9Diagnostic delay in women with cancer: What do we know and which factors contribute? (2025)The Breast, 80. Article 104427. Hoveling, L. A., Schuurman, M., Siesling, S., van Asselt, K. M. & Bode, C.https://doi.org/10.1016/j.breast.2025.104427Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapyā€”results of the multicenter UMBRELLA breast cancer cohort (2025)Breast cancer research and treatment, 210(3), 759-769. Jansen, B. A. M., Bargon, C. A., Bouman, M. A., Mink van der Molen, D. R., Postma, E. L., van der Leij, F., Zonnevylle, E., Ruhe, Q., Bruekers, S. E., Maarse, W., Siesling, S., Young-Afat, D. A., Doeksen, A. & Verkooijen, H. M.https://doi.org/10.1007/s10549-025-07613-wSurgery for Classic, Pleomorphic and Non-classic Lobular Carcinoma In Situ: Surgery Rate, Risk of Upstaging and Short-Term Follow-Up (2025)Annals of surgical oncology, 32(4), 2545–2553 . Meurs, C. J. C., Kerkhoven, C., Siesling, S., Menke-Pluijmers, M. B. E. & Westenend, P. J.https://doi.org/10.1245/s10434-024-16686-8The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis (2025)The Breast, 80. Article 104425. Claassens, E. L., Ploumen, R. A. W., Kooreman, L. F. S., van Kats, M. A. C. E., Siesling, S., van Nijnatten, T. J. A. & Smidt, M. L.https://doi.org/10.1016/j.breast.2025.104425Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype (2025)Journal of the National Cancer Center (E-pub ahead of print/First online). Vrancken Peeters, N. J. M. C., van der Meer, D. J., Kok, M., van Maaren, M. C., Baas-Vrancken Peeters, M.-J. T. F. D., Siesling, S., van der Graaf, W. T. A. & Husson, O.https://doi.org/10.1016/j.jncc.2025.01.005Perspectives of health care professionals on the value of physical examinations for early detection of breast cancer recurrences: more than just a detection method? (2025)Measurement and Evaluations in Cancer Care, 100016 (E-pub ahead of print/First online). Dekker-Klaassen, A., Godding, L. T. H., van Hezewijk, M., Korevaar, J. C., Wiegersma, J., Drossaert, C. H. C. & Siesling, S.https://doi.org/10.1016/j.ymecc.2025.100016Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlandsā€“A Nationwide Overview From 2008 Until 2022 (2025)Clinical oncology, 38. Article 103740. Evers, J., van der Sangen, M. J. C., van Maaren, M. C., Maduro, J. H., Strobbe, L., Aarts, M. J., Bloemers, M. C. W. M., Wesseling, J., van den Bongard, D. H. J. G., Struikmans, H. & Siesling, S.https://doi.org/10.1016/j.clon.2024.103740High-impact complications after breast cancer surgery in the Dutch national quality registry: evaluating case-mix adjustment for hospital comparisons (2025)BJS open, 9(1). Article zrae147. Verheul, E. M., Van Klaveren, D., Lingsma, H. F., Vos, E., Hoornweg, M. J., Siesling, S. & Koppert, L. B.https://doi.org/10.1093/bjsopen/zrae147Surgical treatment after neoadjuvant systemic therapy for HER2-positive invasive breast cancer in the Netherlands: 10-Year trends and the influence an accompanying DCIS component (2025)The Breast, 79. Article 103854. Ploumen, R. A. W., van Nijnatten, T. J. A., Kooreman, L. F. S., Voogd, A. C., Keymeulen, K. B. M. I., Siesling, S. & Smidt, M. L.https://doi.org/10.1016/j.breast.2024.103854The INFLUENCE 3.0 model: updated predictions of locoregional recurrence and contralateral breast cancer, now also suitable for patients treated with neoadjuvant systemic therapy (2025)The Breast, 79. Article 103829. van Maaren , M. C., Hueting, T. A., van Uden, D. J. P., van Hezewijk, M., de Munck, L., Mureau, M. A. M., Seegers, P. A., Voorham, Q. J. M., Schmidt, M. K., Sonke, G. S., Groothuis-Oudshoorn, C. G. M. & Siesling, S.https://doi.org/10.1016/j.breast.2024.103829Working toward Personalized Intervention Advice: A Survey Study on Preference Heterogeneity in Patients with Breast Cancerā€“Related Fatigue (2025)MDM Policy and Practice, 10(1). Beenhakker, L., Wijlens, K. A. E., Bode, C., Vollenbroek-Hutten, M. M. R., Siesling, S., van Til, J. & Witteveen, A.https://doi.org/10.1177/23814683241309676The added value of physical examination for breast cancer recurrence detection in women: A systematic review (2025)Clinical breast cancer (E-pub ahead of print/First online). Godding, L. T. H., Klaassen-Dekker, A., Volders, J. H., van Hezewijk, M., Siemerink, E. J. M., van Uden, D., Veltman, J., Eijkelboom, A. & Siesling, S.https://doi.org/10.1016/j.clbc.2024.12.01470-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ā€‰breast cancer patients: 7-year follow-up of a prospective multicenter cohort study (2025)Breast cancer research and treatment, 209, 331–340. Verreck, E. E. F., Kuijer, A., van Steenhoven, J. E. C., Volders, J. H., van der Velden, A. W. G., Siesling, S., Timmer-Bonte, A. N. H., Smilde, T. J., Imholz, A. L. T., Blanken-Peeters, C. F. J. M., de Valk, B., Vrijaldenhoven, S., Lastdrager, W. B., Haringhuizen, A. W., Hunting, J. C. B., Hovenga, S., Nieboer, P., Zuetenhorst, H. M., Tetteroo, G. W. M., ā€¦ van Dalen, T.https://doi.org/10.1007/s10549-024-07496-3

2024

Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study (2024)Cancers, 16(24). Article 4188. de Bruijn, A., Schipper, R.-J., Voogd, A. C., Pullens, M. J. J., Bloemen, J. G., de Munck, L., van Riet, Y. E., Siesling, S., Vriens, B. E. P. & Nieuwenhuijzen, G. A. P.https://doi.org/10.3390/cancers16244188Data-driven decision support for multidisciplinary clinical decision-making & reporting in breast cancer (2024)[Thesis › PhD Thesis - Research UT, graduation UT]. University of Twente. Hendriks, M. P.https://doi.org/10.3990/1.9789036563390

Research profiles

Scan the QR code or
Download vCard